BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, Angiolillo DJ, Valgimigli M, Testa L, Gaita F. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011;150:325-331. [PMID: 20828843 DOI: 10.1016/j.ijcard.2010.08.035] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Abdel-Qadir H, Roifman I, Wijeysundera HC. Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model. CMAJ Open 2015;3:E438-46. [PMID: 26770967 DOI: 10.9778/cmajo.20150056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
2 Plakht Y, Shiyovich A, Gilutz H. Predictors of long-term (10-year) mortality postmyocardial infarction: age-related differences. Soroka Acute Myocardial Infarction (SAMI) Project. J Cardiol 2015;65:216-23. [PMID: 24994020 DOI: 10.1016/j.jjcc.2014.06.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
3 Tomizawa A, Ohno K, Jakubowski JA, Mizuno M, Sugidachi A. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation. Thromb Haemost 2013;110:769-76. [PMID: 23903326 DOI: 10.1160/TH13-03-0260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Ferri N, Corsini A, Bellosta S. Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. Drugs 2013;73:1681-709. [DOI: 10.1007/s40265-013-0126-z] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
5 Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc Drugs Ther 2016;30:177-88. [PMID: 26780905 DOI: 10.1007/s10557-015-6636-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
6 Falcão FJ, Carvalho L, Chan M, Alves CM, Carvalho AC, Caixeta AM. P2Y12 platelet receptors: importance in percutaneous coronary intervention. Arq Bras Cardiol 2013;101:277-82. [PMID: 23917456 DOI: 10.5935/abc.20130162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Yudi MB, Clark DJ, Farouque O, Eccleston D, Andrianopoulos N, Duffy SJ, Brennan A, Lefkovits J, Ramchand J, Yip T, Oqueli E, Reid CM, Ajani AE; Melbourne Interventional Group. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J 2016;46:559-65. [PMID: 26909472 DOI: 10.1111/imj.13041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
8 Gorla R, Loffi M, Verna E, Margonato A, Salerno-Uriarte J. Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes. J Cardiovasc Med (Hagerstown) 2014;15:532-42. [PMID: 24922044 DOI: 10.2459/JCM.0b013e328365c0fc] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology 2012;60:193-9. [DOI: 10.1016/j.jacc.2012.03.050] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 16.6] [Reference Citation Analysis]
10 Effron MB, Nair KV, Molife C, Keller SY, Page RL 2nd, Simeone JC, Murphy B, Nordstrom BL, Zhu Y, McCollam PL, Vetrovec GW. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. Am J Cardiovasc Drugs 2018;18:129-41. [PMID: 29222628 DOI: 10.1007/s40256-017-0255-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol 2013;169:82-9. [PMID: 23347039 DOI: 10.1111/bph.12108] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
12 Khan MS, Memon MM, Usman MS, Alnaimat S, Khan SU, Khan AR, Yamani N, Fugar S, Mookadam F, Krasuski RA, Doukky R. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs 2019;19:465-76. [DOI: 10.1007/s40256-019-00337-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
13 Plakht Y, Gilutz H, Shiyovich A. Decreased admission serum albumin level is an independent predictor of long-term mortality in hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction II (SAMI-II) project. Int J Cardiol 2016;219:20-4. [PMID: 27257851 DOI: 10.1016/j.ijcard.2016.05.067] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
14 Biondi-zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C, Stabile A, Petronio AS, Binetti G, Bolognese L, Bellone P, Sardella G, Contarini M, Sheiban I, Marra S, Piscione F, Romeo F, Colombo A, Sangiorgi G. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial. American Heart Journal 2012;163:835.e1-7. [DOI: 10.1016/j.ahj.2012.02.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
15 Siller-matula JM, Hintermeier A, Kastner J, Kreiner G, Maurer G, Kratochwil C, Lang IM, Delle-karth G. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascular Pharmacology 2016;79:6-10. [DOI: 10.1016/j.vph.2016.01.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
16 Alber HF, Huber K, Pachinger O, Frick M. Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose? Wien Klin Wochenschr 2011;123:468-76. [DOI: 10.1007/s00508-011-0027-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Chen W, Zhang C, Zhao J, Xu X, Dang H, Xiao Q, Li Y, Hou H. Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta-analysis. Clin Cardiol 2021;44:488-94. [PMID: 33704801 DOI: 10.1002/clc.23536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Cohen Arazi H, Chirino D, Costabel JP, Pulmari CA, Hirschson Prado A, Barba V, Agüero P, Badimon JJ. Leuko-platelet index predicts thrombotic events in patients with acute coronary syndrome. Int J Cardiol 2021;328:29-34. [PMID: 33301835 DOI: 10.1016/j.ijcard.2020.11.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lyseng-williamson KA. Prasugrel: A Guide to Its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the US: . American Journal Cardiovascular Drugs 2012;12:207-16. [DOI: 10.2165/11209640-000000000-00000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 D'ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, Stone GW, Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-zoccai G. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology 2013;167:575-84. [DOI: 10.1016/j.ijcard.2012.01.080] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Bonsu KO, Reidpath DD, Kadirvelu A. Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials. Cardiovasc Ther 2015;33:338-46. [DOI: 10.1111/1755-5922.12150] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
22 Jiang M, You JH. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Cardiovasc Drugs Ther 2017;31:39-49. [PMID: 27924429 DOI: 10.1007/s10557-016-6705-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
23 Kim HN, Lee JH, Kim HJ, Park BE, Jang SY, Bae MH, Yang DH, Park HS, Cho Y, Jeong MH, Park JS, Kim HS, Hur SH, Seong IW, Cho MC, Kim CJ, Chae SC; Korea Acute Myocardial Infarction Registry – National Institute of Health Investigators. Derivation and validation of a combined in-hospital mortality and bleeding risk model in acute myocardial infarction. Int J Cardiol Heart Vasc 2021;33:100732. [PMID: 33665352 DOI: 10.1016/j.ijcha.2021.100732] [Reference Citation Analysis]
24 Hulot J, Hajjar R, Montalescot G. Clopidogrel and CYP2C19 Testing: Ready for Clinical Prime Time? Clinical Chemistry 2012;58:154-7. [DOI: 10.1373/clinchem.2011.165829] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Simeone JC, Molife C, Marrett E, Frech-Tamas F, Effron MB, Nordstrom BL, Zhu YE, Keller S, Murphy BR, Nair KV, Vetrovec GW, Page RL 2nd, McCollam PL. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Am J Cardiovasc Drugs 2015;15:337-50. [PMID: 26359016 DOI: 10.1007/s40256-015-0147-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
26 Predazzi IM, Mango R, Norata GD, Di Daniele N, Sergi D, Romeo F, Novelli G. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. Am J Cardiovasc Drugs 2013;13:79-85. [PMID: 23539170 DOI: 10.1007/s40256-013-0020-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 D'Ascenzo F, Colombo F, Barbero U, Moretti C, Omedè P, Reed MJ, Tarantini G, Frati G, Di Nicolantonio JJ, Biondi Zoccai G, Gaita F. Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. J Interv Cardiol 2014;27:233-41. [PMID: 24627967 DOI: 10.1111/joic.12107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
28 Aït Mokhtar O, Gaubert M, Laine M, Bonello L, Guieu R, Cautela J, Peyrol M, Barraud J, Thuny F, Dignat-Georges F, Sabatier F, Fromonot J, Rossi P, Paganelli F. Pleiotropic effects of ticagrelor: Myth or reality? Arch Cardiovasc Dis 2016;109:445-8. [PMID: 27342807 DOI: 10.1016/j.acvd.2016.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
29 Steiner S, Moertl D, Chen L, Coyle D, Wells GA. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost 2012;108:318-27. [PMID: 22627948 DOI: 10.1160/TH11-08-0586] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
30 Capranzano P, Capodanno D. Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Review of Cardiovascular Therapy 2014;11:307-17. [DOI: 10.1586/erc.13.3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
31 Aytekin A, Ndrepepa G, Neumann F, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, Trenk D, Fusaro M, Laugwitz K, Schunkert H, Schüpke S, Kastrati A. Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation 2020;142:2329-37. [DOI: 10.1161/circulationaha.120.050244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 12.0] [Reference Citation Analysis]
32 Rasia M, Solinas E, Marino M, Guastaroba P, Menozzi A, Cattabiani MA, Tadonio I, De Palma R, Vignali L. Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry. J Thromb Thrombolysis 2017;44:466-74. [PMID: 28994036 DOI: 10.1007/s11239-017-1567-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Biondi Zoccai G, Abbate A, D'Ascenzo F, Presutti D, Peruzzi M, Cavarretta E, Marullo AG, Lotrionte M, Frati G. Percutaneous coronary intervention in nonagenarians: pros and cons. J Geriatr Cardiol 2013;10:82-90. [PMID: 23610578 DOI: 10.3969/j.issn.1671-5411.2013.01.013] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
34 Martí D, Salido L, Mestre JL, Esteban MJ, Casas E, Jiménez-mena M, Pey J, Sanmartín M, Hernández-antolín R, Zamorano JL. Impact of thrombus burden on procedural and mid-term outcomes after primary percutaneous coronary intervention. Coronary Artery Disease 2016;27:169-75. [DOI: 10.1097/mca.0000000000000317] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, Yanagawa B, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg 2015;15:112. [PMID: 26467661 DOI: 10.1186/s12893-015-0096-z] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
36 Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, Karkare S, Lieu HD, Lee WC, Vetrovec GW. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Catheter Cardiovasc Interv 2016;88:535-44. [PMID: 26577386 DOI: 10.1002/ccd.26279] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
37 Prati F, Di Vito L, Ramazzotti V, Imola F, Pawlowski T, Materia L, Tavazzi L, Biondi-Zoccai G, Albertucci M. Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCTAIL II study. J Cardiovasc Med (Hagerstown) 2013;14:364-71. [PMID: 22929568 DOI: 10.2459/JCM.0b013e3283586fee] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
38 Hermanides RS, Kilic S, van 't Hof AWJ. Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI. Neth Heart J 2018;26:296-310. [PMID: 29687412 DOI: 10.1007/s12471-018-1112-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
39 Halbach M, Baldus S. [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]. Internist (Berl) 2018;59:288-303. [PMID: 29340741 DOI: 10.1007/s00108-017-0362-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, Oreglia J, Latib A, Pizzocri S, Laudisa ML. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM. 2012;105:949-957. [PMID: 22771555 DOI: 10.1093/qjmed/hcs114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
41 Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K. Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. Neurosurgery 2019;84:77-83. [DOI: 10.1093/neuros/nyy002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
42 Nawarskas JJ, Snowden SS. Critical appraisal of ticagrelor in the management of acute coronary syndrome. Ther Clin Risk Manag 2011;7:473-88. [PMID: 22241944 DOI: 10.2147/TCRM.S19835] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
43 Silber H, Shiyovich A, Gilutz H, Ziedenberg H, Abu Tailakh M, Plakht Y. Decreased Norton's functional score is an independent long-term prognostic marker in hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction II (SAMI-II) project. Int J Cardiol 2017;228:694-9. [PMID: 27886612 DOI: 10.1016/j.ijcard.2016.11.112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
44 Cayla G, Silvain J, O'connor SA, Collet J, Montalescot G. An evidence-based review of current anti-platelet options for STEMI patients. International Journal of Cardiology 2013;166:294-303. [DOI: 10.1016/j.ijcard.2012.04.160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
45 De Filippo O, Cortese M, D´ascenzo F, Raposeiras-roubin S, Abu-assi E, Kinnaird T, Ariza-solé A, Manzano-fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A, Boccuzzi G, Montefusco A, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Garay A, Quadri G, Varbella F, Queija BC, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-rodriguez A, Valdés M, Cequier A, Alexopoulos D, Iñiguez-romo A, Rinaldi M. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. Am J Cardiovasc Drugs 2019;19:381-91. [DOI: 10.1007/s40256-019-00339-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
46 Husted S, Boersma E. Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. Am J Ther 2016;23:e1876-89. [PMID: 25830867 DOI: 10.1097/MJT.0000000000000237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
47 Biondi-Zoccai G, Versaci F, Frati G. Focusing on kidneys and platelets in acute coronary syndromes: pre hoc and post hoc risk profiling. J Cardiovasc Med (Hagerstown) 2020;21:667-8. [PMID: 32520866 DOI: 10.2459/JCM.0000000000001003] [Reference Citation Analysis]
48 Plakht Y, Shiyovich A, Weitzman S, Fraser D, Zahger D, Gilutz H. Soroka acute myocardial infarction (SAMI) score predicting 10-year mortality following acute myocardial infarction. International Journal of Cardiology 2013;167:3068-70. [DOI: 10.1016/j.ijcard.2012.11.075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
49 Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol 2012;21:187-94. [PMID: 24293975 DOI: 10.1055/s-0032-1330232] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
50 Bauer T, Hamm C. Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice. Interv Cardiol 2014;9:164-7. [PMID: 29588796 DOI: 10.15420/icr.2014.9.3.164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
51 Ray A, Najmi A, Khandelwal G, Jhaj R, Sadasivam B. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. Cardiovasc Drugs Ther 2021;35:561-74. [PMID: 32816142 DOI: 10.1007/s10557-020-07056-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Nusca A, Patti G. Platelet Function and Inhibition in Ischemic Heart Disease. Curr Cardiol Rep 2012;14:457-67. [DOI: 10.1007/s11886-012-0280-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
53 Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, McEntee J, Dundar Y, Richardson M, Fisher M. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technol Assess 2015;19:1-130. [PMID: 25896573 DOI: 10.3310/hta19290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Tan Q, Jiang X, Huang S, Zhang T, Chen L, Xie S, Mo E, Xu J, Cai S. The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis. PLoS One 2017;12:e0177872. [PMID: 28545073 DOI: 10.1371/journal.pone.0177872] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
55 Davis EM, Knezevich JT, Teply RM. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Clin Pharmacol 2013;5:67-83. [PMID: 23650452 DOI: 10.2147/CPAA.S41859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Khayata M, Gabra JN, Nasser MF, Litman GI, Bhakta S, Raina R. Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry. Cardiol Res 2017;8:105-10. [PMID: 28725326 DOI: 10.14740/cr560w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
57 Curial M, Nath E, Lang E. Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a review. Cardiol Res Pract 2013;2013:127270. [PMID: 23509665 DOI: 10.1155/2013/127270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Boden H, van der Hoeven BL, Karalis I, Schalij MJ, Jukema JW. Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment: Review: Management of acute coronary syndrome. Journal of Internal Medicine 2012;271:521-36. [DOI: 10.1111/j.1365-2796.2012.02533.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
59 Berger JS. Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. Am J Cardiovasc Drugs 2018;18:457-72. [PMID: 29987548 DOI: 10.1007/s40256-018-0291-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
60 Norgard NB, Dinicolantonio JJ. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med 2013;125:91-102. [PMID: 23933898 DOI: 10.3810/pgm.2013.07.2682] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
61 Kim HJ, Oh JS, Park SQ, Yoon SM, Ahn HS, Kim BT. The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis. J Korean Neurosurg Soc 2020;63:539-49. [PMID: 31661948 DOI: 10.3340/jkns.2019.0082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
62 Watti H, Dahal K, Zabher HG, Katikaneni P, Modi K, Abdulbaki A. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. International Journal of Cardiology 2017;249:66-72. [DOI: 10.1016/j.ijcard.2017.07.103] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
63 van Leeuwen MAH, van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Ten Cate TJF, Piek JJ, von Birgelen C, Escaned J, Valgimigli M, Diletti R, Riksen NP, van Mieghem NM, Nijveldt R, van Royen N. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. Circulation 2019;139:636-46. [PMID: 30586720 DOI: 10.1161/CIRCULATIONAHA.118.035931] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 10.5] [Reference Citation Analysis]
64 Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W. Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Rev Cardiovasc Ther 2012;10:489-503. [PMID: 22458581 DOI: 10.1586/erc.12.20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
65 Adamski P, Koziński M, Ostrowska M, Fabiszak T, Navarese EP, Paciorek P, Grześk G, Kubica J. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost 2014;112:224-42. [PMID: 24763899 DOI: 10.1160/TH13-11-0915] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 3.9] [Reference Citation Analysis]
66 Xia M, Zhang C, Gu J, Chen J, Wang LC, Lu Y, Huang CY, He YM, Yang XJ. Impact of C-reactive protein on long-term mortality in acute myocardial infarction patients with diabetes and those without. Clin Chim Acta 2018;480:220-4. [PMID: 29476733 DOI: 10.1016/j.cca.2018.02.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Plakht Y, Gilutz H, Shiyovich A. Excess long-term mortality among hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction (SAMI) project. Public Health 2017;143:25-36. [PMID: 28159024 DOI: 10.1016/j.puhe.2016.09.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
68 Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis 2013;36:223-32. [PMID: 23212803 DOI: 10.1007/s11239-012-0838-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
69 Widimský P, Jukema J, Meier B, Trenk D, Collet JP, Frick M, Roffi M. Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents. Cor Vasa 2012;54:e32-8. [DOI: 10.1016/j.crvasa.2011.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 D'ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, Stone GW, Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-zoccai G. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology 2013;167:575-84. [DOI: 10.1016/j.ijcard.2012.01.080] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 12.8] [Reference Citation Analysis]
71 Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:711-719. [PMID: 22912382 DOI: 10.1161/circoutcomes.112.966572] [Cited by in Crossref: 83] [Cited by in F6Publishing: 29] [Article Influence: 9.2] [Reference Citation Analysis]
72 Capodanno D, Calvi V, Tamburino C. Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine 2012;13:162-3. [DOI: 10.2459/jcm.0b013e32834f23bd] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, Pirker-kees A, Siller-matula JM. Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases: A Systematic Review and Meta-Analysis. Stroke 2014;45:492-503. [DOI: 10.1161/strokeaha.113.002590] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 6.9] [Reference Citation Analysis]
74 Braun OÖ, Bico B, Chaudhry U, Wagner H, Koul S, Tydén P, Scherstén F, Jovinge S, Svensson PJ, Gustav Smith J, van der Pals J. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thrombosis Research 2015;135:26-30. [DOI: 10.1016/j.thromres.2014.10.016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
75 Piccolo R, Gioia GD, Niglio T, D’anna C, Rosa RD, Strisciuglio T, Bevilacqua M, Piscione F, Cirillo P, Galasso G. Pharmacotherapeutic Considerations for the Use of Prasugrel and Ticagrelor to Reduce Stent Thrombosis in Patients With Acute Coronary Syndrome. Angiology 2014;65:130-6. [DOI: 10.1177/0003319712467530] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
76 Deharo P, Loosveld M, Bonnet G, Pankert M, Quilici J, Lambert M, Verdier V, Morange P, Bonnet J, Alessi M, Cuisset T. Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. IJC Heart & Vessels 2014;4:188-92. [DOI: 10.1016/j.ijchv.2014.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
77 D'ascenzo F, Biondi-zoccai G. Network Meta-Analyses: The “White Whale” for Cardiovascular Specialists. Journal of Cardiothoracic and Vascular Anesthesia 2014;28:169-73. [DOI: 10.1053/j.jvca.2013.01.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
78 Conrotto F, Bertaina M, Raposeiras-roubin S, Kinnaird T, Ariza-solé A, Manzano-fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A, Boccuzzi G, Omedè P, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Quadri G, Varbella F, Caneiro Queija B, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Dominguez-rodriguez A, Valdés M, Cequier A, Alexopoulos D, Iñiguez-romo A, Gaita F, Abu-assi E, D’ascenzo F. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. European Heart Journal: Acute Cardiovascular Care 2018;8:536-42. [DOI: 10.1177/2048872618802783] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
79 Cammisotto V, Biondi-Zoccai G, Frati G, Giordano A. Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy? Am J Cardiovasc Drugs 2019;19:377-9. [PMID: 31030412 DOI: 10.1007/s40256-019-00340-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Biondi-Zoccai G, Anderson LA. What is the purpose of launching World Journal of Meta-AnalysisWorld J Meta-Anal 2013; 1(1): 1-4 [DOI: 10.13105/wjma.v1.i1.1] [Reference Citation Analysis]
81 Ramaraj R, Movahed MR, Hashemzadeh M. Novel Antiplatelet Agent Ticagrelor in the Management of Acute Coronary Syndrome: TICAGRELOR AND ACUTE CORONARY SYNDROME. Journal of Interventional Cardiology 2011;24:199-207. [DOI: 10.1111/j.1540-8183.2010.00613.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
82 Clemmensen P, Dridi NP, Holmvang L. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovasc Drugs Ther 2013;27:239-45. [PMID: 23380983 DOI: 10.1007/s10557-013-6444-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
83 Packard KA, Campbell JA, Knezevich JT, Davis EM. Emerging Antiplatelet Therapy for Coronary Artery Disease and Acute Coronary Syndrome. Pharmacotherapy 2012;32:244-73. [DOI: 10.1002/j.1875-9114.2012.01021.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]